Collaboration and joint research Call: Recently we conducted studies on BRCA1, BRCA2, EGFR, and ESR1 mutations in cancer! Our computational approach identified potential pathogenic variations in these genes, increasing the risk of cancer development. However, with limited funds, instead of using sequencing, we intend to utilise ARMS-PCR for experimental validation. Notably, the predicted SNPs are not found in literature showing risk with cancer. How do we select and validate these SNPs for further investigation? Let's discuss strategies for bridging the gap between bioinformatics predictions and experimental validation in cancer research. hashtag#CancerResearch hashtag#BRCA1 hashtag#BRCA2 hashtag#ESR1 hashtag#EGFR hashtag#Bioinformatics hashtag#WetLabE

More Najeeb Ullah Khan's questions See All
Similar questions and discussions